Evaluating ELISPOT summary measures with criteria for obtaining reliable estimates

Journal of Immunological Methods

Volumn 297, Issue 1-2, 2005, Pages 97-108

  Zeng, Chan ^a   MaWhinney, Samantha ^a   Barón, Anna E ^a   McFarland, Elizabeth J ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b CHILDREN S HOSPITAL   (United States)

Author keywords

CD8+; ELISPOT assay; HIV AIDS; IFN ; Mixed models; Nonlinear Poisson regression

Indexed keywords

ACCURACY; ARTICLE; BIOASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; INFORMATION PROCESSING; NONHUMAN; PRIORITY JOURNAL; REGRESSION ANALYSIS; RELIABILITY; SIMULATION; STATISTICAL ANALYSIS;

EID: 15244342437     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2004.12.006     Document Type: Article

References (23)

1. M. Altfeld, J. van Lunzen, N. Frahm, X.G. Yu, C. Schneider, R.L. Eldridge, M.E. Feeney, D. Meyer-Olson, H.J. Stellbrink, and B.D. Walker Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection J. Clin. Invest. 109 6 2002 837 (March)
2. T. Asai, W.J. Storkus, and T.L. Whiteside Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines Clin. Diagn. Lab. Immunol. 7 2 2000 145
3. L.H. Carvalho, J.C. Hafalla, and F. Zavala ELISPOT assay to measure antigen-specific murine CD8 (+) T cell responses J. Immunol. Methods 252 2001 207
4. C. Czerkinsky, G. Adersson, H.P. Ekre, L.A. Nielsson, L. Klaereskog, and O. Ouchterlony Reverse ELISPOT assay for clonal analysis of cytokine production: I. Enumeration of gamma-interferon secreting cells J. Immunol. Methods 110 1988 29
5. G.E. ElGhazali, S. Paulie, G. Andersson, Y. Hansson, G. Holmquist, J.B. Sun, T. Olsson, H.P. Ekre, and M. Troye-Blomberg Number of interleukin-4- and interferon-gamma-secreting human T cells reactive with tetanus toxoid and the mycobacterial antigen PPD or phytohemagglutinin: distinct response profiles depending on the type of antigen used for activation Eur. J. Immunol. 23 11 1993 2740
6. M.C. Ellison, G.O. Zerbe, and M.J. Levin Responder cell frequency estimation and binomial three-level nonlinear mixed effects model in limiting dilution assays J. Biopharm. Stat. 15 1 2005 165
7. + T lymphocytes secreting TNFα in response to HLA-A2.1-binding melanoma and viral peptide antigens J. Immunol. Methods 191 1996 131
8. + T lymphocytes producing TNFα spots in response to peptide antigens J. Immunol. Methods 203 1997 141
9. + memory T cells J. Exp. Med. 186 6 1997 859
10. M. Larsson, X. Jin, B. Ramratnam, G.S. Ogg, J. Engelmayer, M.A. Demoitie, A.J. McMichael, W.I. Cox, R.M. Steinman, D. Nixon, and N. Bhardwaj A recombinant vaccinia virus based on ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals AIDS 13 1999 767
11. N.M. Laird, and J.H. Ware Random effects models for longitudinal data Biometrics 38 1982 963
12. R.J.A. Little, and D.B. Rubin Statistical analysis with missing data 2nd edition 2002 John Wiley New York
13. M. McCutcheon, N. Wehner, A. Wensky, M. Kushner, S. Doan, L. Hsiao, P. Calabresi, T. Ha, T.V. Tran, K.M. Tate, J. Winkelhake, and E.G. Spack A sensitive ELISPOT assay to detect low-frequency human T lymphocytes J. Immunol. Methods 210 2 1997 149
14. C.A. Power, C.L. Grand, N. Ismail, N.C. Peters, D.P. Yurkowski, and P.A. Bretscher A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFN gamma-producing T cells J. Immunol. Methods 227 1999 99
15. + T lymphocytes specific for HLA class I-binding peptide epitopes derived from influenza protein in the blood of healthy donors ans melanoma patients Clin. Cancer Res. 3 1997 221
16. R. Schlichtemeier, J. Folkvord, A. Mian, D. Anderson, S. MaWhinney, and E. Connick HIV-specific CTL in lymph nodes in recent and chronic infection (abstract 273) 8th Conference on retroviruses and opportunistic infections. Chicago, February 4-8, 2001 2001
17. A. Schmittel, U. Keilholz, and C. Scheibenbogen Evaluation of the interferon-gamma ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral blood J. Immunol. Methods 210 2 1997 167
18. A. Schmittel, U. Keilholz, E. Thiel, and C. Scheibenbogen Quantification of tumor-specific T lymphocytes with the ELISPOT assay J. Immunother. 23 2000 289
19. G.O. Skeie, P.T. Bentsen, A. Freiburg, J.A. Aarli, and N.E. Gilhus Cell-mediated immune response against titin in myasthenia gravis: evidence for the involvement of Th1 and Th2 cells Scand. J. Immunol. 47 1 1998 76
20. J.G. Smith, X. Liu, R.M. Kaufhold, J. Clair, and M.J. Caulfield Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus Clin. Diagn. Lab. Immunol. 8 5 2001 871
21. E.J. Stanek III, A. Well, and I. Ockene Why not routinely use best linear unbiased predictors (BLUPs) as estimates of cholesterol, per cent fat from kcal and physical activity? Stat. Med. 18 1999 2943
22. S.E. Starr, E.J. McFarland, P. Muresan, T. Fenton, J. Pitt, S.D. Douglas, A. Deveikis, J.J. Levin, M.H. Rathore the PACTG 299 Study Team Phase I/II trial of intravenous recombinant Interleukin-2 in Human Immunodeficiency Virus-infected children AIDS 17 2003 2181
23. R.A. Thisted Elements of Statistical Computing 1988 Chapman and Hall New York 264